Posted by Michael Wonder on 02 Jul 2020
scPharmaceuticals announces Furoscix NDA resubmission
1 July 2020 - scPharmaceuticals today announced that it has resubmitted its 505(b)(2) new drug application to the U.S. FDA seeking approval of Furoscix (subcutaneous furosemide) for the treatment of congestion in patients with heart failure.
The resubmission is intended to address concerns raised in the FDA’s June 2018 complete response letter.
